Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	25.84B -19.6%
Revenue (ttm)	3.70B +31.2%
Net Income	1.03B +24.6%
EPS	2.52 +24.1%
Shares Out	408.19M
PE Ratio	25.12
Forward PE	19.97
Dividend	0.62 (0.98%)
Ex-Dividend Date	May 9, 2025

Volume	1,887,711
Average Volume	2,186,173
Open	64.00
Previous Close	63.50
Day's Range	62.80 - 64.00
52-Week Range	61.65 - 93.52
Beta	-0.02
RSI	36.12
Earnings Date	Mar 27, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,685
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.03 billion, an increase of 24.61%.